[Efficacy of detection of specific nuclear protein of matrix 22 in the urine in diagnosis of urinary bladder cancer].
The method is based on enzyme immunoassay for definition of nuclear matrix proteins forming part of the cell nuclear capsule. Quantity of these proteins increase 20-80 times in cancer of the bladder. A total of 83 patients participated in the trial. Group 1 consisted of 18 patients with primary bladder cancer, group 2 - of 26 patients with histologically confirmed bladder cancer recurrence. Group 3 - 19 patients with operated bladder cancer without recurrent disease for at least 6 months. Control group - 20 healthy donors. The test urine sample was placed into a test hole and 30 min later the result was assessed. Overall sensitivity of the method was 52% (p < 0.05). Sensitivity of the test increases with progression of the disease: T1 - 37%, T2 - 75%, T3 - 80% (p < 0.05); G1 - 30%, G2 - 50%, G3 87% (p < 0.05). Overall specificity was 95% (p < 0.05). Thus, nuclear matrix proteins 22 represent a prospective marker of the bladder cancer with high specificity and sensitivity in defining not only primary tumors but also the disease recurrences.